Multidrug resistance-associated protein 2 (Mrp2) mediates biliary secretion of anionic endobiotics and xenobiotics. Genetic alteration of Mrp2 leads to conjugated hyperbilirubinemia and predisposes to the development of intrahepatic cholestasis of pregnancy (ICP), characterized by increased plasma bile acids (BAs) due to mechanisms that are incompletely understood. Therefore, this study aimed to characterize BA metabolomics during experimental Mrp2 deficiency and ICP. ICP was modeled by ethinylestradiol (EE) administration to Mrp2-deficient (TR) rats and their wild-type (WT) controls. Spectra of BAs were analyzed in plasma, bile, and stool using an advanced liquid chromatography-mass spectrometry (LC-MS) method. Changes in BA-related genes and proteins were analyzed in the liver and intestine. Vehicle-administered TR rats demonstrated higher plasma BA concentrations consistent with reduced BA biliary secretion and increased BA efflux from hepatocytes to blood via upregulated multidrug resistance-associated protein 3 (Mrp3) and multidrug resistance-associated protein 4 (Mrp4) transporters. TR rats also showed a decrease in intestinal BA reabsorption due to reduced ileal sodium/bile acid cotransporter (Asbt) expression. Analysis of regulatory mechanisms indicated that activation of the hepatic constitutive androstane receptor (CAR)-Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway by accumulating bilirubin may be responsible for changes in BA metabolomics in TR rats. Ethinylestradiol administration to TR rats further increased plasma BA concentrations as a result of reduced BA uptake and increased efflux via reduced Slco1a1 and upregulated Mrp4 transporters. These results demonstrate that Mrp2-deficient organism is more sensitive to estrogen-induced cholestasis. Inherited deficiency in Mrp2 is associated with activation of Mrp3 and Mrp4 proteins, which is further accentuated by increased estrogen. Bile acid monitoring is therefore highly desirable in pregnant women with conjugated hyperbilirubinemia for early detection of intrahepatic cholestasis.

Department of Medical Biochemistry Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czechia

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czechia

Department of Pharmacology Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czechia

Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN United States

Zobrazit více v PubMed

Akita H., Suzuki H., Ito K., Kinoshita S., Sato N., Takikawa H., et al. . (2001). Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta 1511, 7–16. doi: 10.1016/s0005-2736(00)00355-2, PMID: PubMed DOI

Akita H., Suzuki H., Sugiyama Y. (2002). Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. Biochem. Biophys. Res. Commun. 299, 681–687. doi: 10.1016/s0006-291x(02)02723-7, PMID: PubMed DOI

Aleksunes L. M., Klaassen C. D. (2012). Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice. Drug Metab. Dispos. 40, 1366–1379. doi: 10.1124/dmd.112.045112, PMID: PubMed DOI PMC

Aleksunes L. M., Slitt A. L., Maher J. M., Augustine L. M., Goedken M. J., Chan J. Y., et al. . (2008). Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol. 226, 74–83. doi: 10.1016/j.taap.2007.08.022, PMID: PubMed DOI PMC

Aoki M., Konya Y., Takagaki T., Umemura K., Sogame Y., Katsumata T., et al. . (2011). Metabolomic investigation of cholestasis in a rat model using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25, 1847–1852. doi: 10.1002/rcm.5072, PMID: PubMed DOI

Blazquez A. G., Briz O., Romero M. R., Rosales R., Monte M. J., Vaquero J., et al. . (2012). Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol. Pharmacol. 81, 273–283. doi: 10.1124/mol.111.075143, PMID: PubMed DOI

Cermanova J., Kadova Z., Zagorova M., Hroch M., Tomsik P., Nachtigal P., et al. . (2015). Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms. Toxicol. Appl. Pharmacol. 285, 12–22. doi: 10.1016/j.taap.2015.03.004, PMID: PubMed DOI

Chiang J. Y. L., Ferrell J. M. (2020). Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Res. 4, 47–63. doi: 10.1016/j.livres.2020.05.001, PMID: PubMed DOI PMC

Corpechot C., Barbu V., Chazouillères O., Broué P., Girard M., Roquelaure B., et al. . (2020). Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders. Liver Int. 40, 163–174. doi: 10.1111/liv.14260, PMID: PubMed DOI

Crocenzi F. A., Pellegrino J. M., Catania V. A., Luquita M. G., Roma M. G., Mottino A. D., et al. . (2006). Galactosamine prevents ethinylestradiol-induced cholestasis. Drug Metab. Dispos. 34, 993–997. doi: 10.1124/dmd.106.009308, PMID: PubMed DOI

Dixon P. H., Sambrotta M., Chambers J., Taylor-Harris P., Syngelaki A., Nicolaides K., et al. . (2017). An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci. Rep. 7:11823. doi: 10.1038/s41598-017-11626-x, PMID: PubMed DOI PMC

Douglas J. G., Beckett G. J., Percy-Robb I. W., Finlayson N. D. (1980). Bile salt transport in the Dubin-Johnson syndrome. Gut 21, 890–893. doi: 10.1136/gut.21.10.890, PMID: PubMed DOI PMC

Engelking L. R., Gronwall R. (1979). Bile acid clearance in sheep with hereditary hyperbilirubinemia. Am. J. Vet. Res. 40, 1277–1280. PMID: PubMed

Faradonbeh F. A., Sa I., Lastuvkova H., Cermanova J., Hroch M., Faistova H., et al. . (2021). Metformin impairs bile acid homeostasis in ethinylestradiol-induced cholestasis in mice. Chem. Biol. Interact. 345:109525. doi: 10.1016/j.cbi.2021.109525, PMID: PubMed DOI

Fu H., Zhao R., Jia X., Li X., Li G., Yin C. (2021). Neonatal Dubin-Johnson syndrome: biochemical parameters, characteristics, and genetic variants study. Pediatr. Res. doi: 10.1038/s41390-021-01583-7 [Epub ahead of print]. PubMed

Garcia M., Thirouard L., Sedès L., Monrose M., Holota H., Caira F., et al. . (2018). Nuclear receptor metabolism of bile acids and Xenobiotics: a coordinated detoxification system with impact on health and diseases. Int. J. Mol. Sci. 19:3630. doi: 10.3390/ijms19113630, PMID: PubMed DOI PMC

Gavrilova O., Geyer J., Petzinger E. (2007). In vivo relevance of Mrp2-mediated biliary excretion of the amanita mushroom toxin demethylphalloin. Biochim. Biophys. Acta 1768, 2070–2077. doi: 10.1016/j.bbamem.2007.07.006, PMID: PubMed DOI

Geier A., Dietrich C. G., Gerloff T., Haendly J., Kullak-Ublick G. A., Stieger B., et al. . (2003). Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim. Biophys. Acta 1609, 87–94. doi: 10.1016/s0005-2736(02)00657-0, PMID: PubMed DOI

Geier A., Wagner M., Dietrich C. G., Trauner M. (2007). Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773, 283–308. doi: 10.1016/j.bbamcr.2006.04.014, PMID: PubMed DOI

Hirsova P., Karlasova G., Dolezelova E., Cermanova J., Zagorova M., Kadova Z., et al. . (2013). Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2. Toxicology 303, 9–15. doi: 10.1016/j.tox.2012.10.018, PMID: PubMed DOI

Huang L., Smit J. W., Meijer D. K., Vore M. (2000). Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology 32, 66–72. doi: 10.1053/jhep.2000.8263, PMID: PubMed DOI

Huynh M. T., Chrétien Y., Grison S., Delaunay J. L., Lascols O., Tran C. T., et al. . (2018). Novel compound heterozygous ABCC2 variants in patients with Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy. Clin. Genet. 94, 480–481. doi: 10.1111/cge.13420, PMID: PubMed DOI

Jemnitz K., Heredi-Szabo K., Janossy J., Ioja E., Vereczkey L., Krajcsi P. (2010). ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab. Rev. 42, 402–436. doi: 10.3109/03602530903491741, PMID: PubMed DOI

Jiang L., Chu H., Gao B., Lang S., Wang Y., Duan Y., et al. . (2020). Transcriptomic profiling identifies novel hepatic and intestinal genes following chronic plus binge ethanol feeding in mice. Dig. Dis. Sci. 65, 3592–3604. doi: 10.1007/s10620-020-06461-6, PMID: PubMed DOI PMC

Junge N., Goldschmidt I., Wiegandt J., Leiskau C., Mutschler F., Laue T., et al. . (2021). Dubin-Johnson syndrome as differential diagnosis for neonatal cholestasis. J. Pediatr. Gastroenterol. Nutr. 72, e105–e111. doi: 10.1097/mpg.0000000000003061, PMID: PubMed DOI

Koopen N. R., Wolters H., Havinga R., Vonk R. J., Jansen P. L., Muller M., et al. . (1998). Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27, 537–545. doi: 10.1002/hep.510270231, PMID: PubMed DOI

Kuipers F., Enserink M., Havinga R., Van Der Steen A. B., Hardonk M. J., Fevery J., et al. . (1988). Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat. J. Clin. Invest. 81, 1593–1599. doi: 10.1172/jci113493, PMID: PubMed DOI PMC

Kularatnam G. A. M., Warawitage D., Vidanapathirana D. M., Jayasena S., Jasinge E., De Silva N., et al. . (2017). Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy in a Sri Lankan family: a case report. BMC. Res. Notes 10:487. doi: 10.1186/s13104-017-2811-6, PMID: PubMed DOI PMC

Lee J. M., Trauner M., Soroka C. J., Stieger B., Meier P. J., Boyer J. L. (2000). Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118, 163–172. doi: 10.1016/s0016-5085(00)70425-2, PMID: PubMed DOI

Lefebvre P., Benomar Y., Staels B. (2010). Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol. Metab. 21, 676–683. doi: 10.1016/j.tem.2010.06.009, PMID: PubMed DOI

Liu J., Hou L. L., Zhao C. Y. (2018). Effect of YHHJ on the expression of the hepatocellular bile acid transporters multidrug resistance-associated protein 2 and bile salt export pump in ethinylestradiol-induced cholestasis. Exp. Ther. Med. 15, 3699–3704. doi: 10.3892/etm.2018.5891, PMID: PubMed DOI PMC

Liu J., Lickteig A. J., Zhang Y., Csanaky I. L., Klaassen C. D. (2021). Activation of Nrf2 decreases bile acid concentrations in livers of female mice. Xenobiotica 51, 605–615. doi: 10.1080/00498254.2021.1880033, PMID: PubMed DOI

Meier Y., Zodan T., Lang C., Zimmermann R., Kullak-Ublick G. A., Meier P. J., et al. . (2008). Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J. Gastroenterol. 14, 38–45. doi: 10.3748/wjg.14.38, PMID: PubMed DOI PMC

Muchova L., Vanova K., Suk J., Micuda S., Dolezelova E., Fuksa L., et al. . (2015). Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis. J. Cell. Mol. Med. 19, 924–933. doi: 10.1111/jcmm.12401, PMID: PubMed DOI PMC

Oswald S., Westrup S., Grube M., Kroemer H. K., Weitschies W., Siegmund W. (2006). Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J. Pharmacol. Exp. Ther. 318, 1293–1299. doi: 10.1124/jpet.106.104018, PMID: PubMed DOI

Pozzi E. J. S., Crocenzi F. A., Pellegrino J. M., Catania V. A., Luquita M. G., Roma M. G., et al. . (2003). Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 306, 279–286. doi: 10.1124/jpet.103.049940, PMID: PubMed DOI

Prasnicka A., Cermanova J., Hroch M., Dolezelova E., Rozkydalova L., Smutny T., et al. . (2017). Iron depletion induces hepatic secretion of biliary lipids and glutathione in rats. Biochim. Biophys. Acta 1862, 1469–1480. doi: 10.1016/j.bbalip.2017.09.003, PMID: PubMed DOI

Rezai S., Lam J., Henderson C. E. (2015). Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am. J. Obstet. Gynecol. 213:114. doi: 10.1016/j.ajog.2015.03.040, PMID: PubMed DOI

Rooney J. P., Oshida K., Kumar R., Baldwin W. S., Corton J. C. (2019). Chemical activation of the constitutive androstane receptor leads to activation of oxidant-induced Nrf2. Toxicol. Sci. 167, 172–189. doi: 10.1093/toxsci/kfy231, PMID: PubMed DOI PMC

Ruiz M. L., Rigalli J. P., Arias A., Villanueva S. S., Banchio C., Vore M., et al. . (2013). Estrogen receptor-α mediates human multidrug resistance associated protein 3 induction by 17α-ethynylestradiol. Role of activator protein-1. Biochem. Pharmacol. 86, 401–409. doi: 10.1016/j.bcp.2013.05.025, PMID: PubMed DOI

Ruiz M. L., Villanueva S. S., Luquita M. G., Ikushiro S., Mottino A. D., Catania V. A. (2007). Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2. Drug Metab. Dispos. 35, 2060–2066. doi: 10.1124/dmd.107.016519, PMID: PubMed DOI

Sookoian S., Castaño G., Burgueño A., Gianotti T. F., Pirola C. J. (2008). Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J. Hepatol. 48, 125–132. doi: 10.1016/j.jhep.2007.08.015, PMID: PubMed DOI

Stieger B., Fattinger K., Madon J., Kullak-Ublick G. A., Meier P. J. (2000). Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118, 422–430. doi: 10.1016/s0016-5085(00)70224-1, PMID: PubMed DOI

Takikawa H., Sano N., Narita T., Uchida Y., Yamanaka M., Horie T., et al. . (1991). Biliary excretion of bile acid conjugates in a hyperbilirubinemic mutant Sprague-Dawley rat. Hepatology 14, 352–360. PMID: PubMed

Tanaka N., Matsubara T., Krausz K. W., Patterson A. D., Gonzalez F. J. (2012). Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118–129. doi: 10.1002/hep.25630, PMID: PubMed DOI PMC

Togawa T., Mizuochi T., Sugiura T., Kusano H., Tanikawa K., Sasaki T., et al. . (2018). Clinical, pathologic, and genetic features of neonatal Dubin-Johnson syndrome: a multicenter study in Japan. J. Pediatr. 196, 161.e1–167.e1. doi: 10.1016/j.jpeds.2017.12.058, PMID: PubMed DOI

Trauner M., Arrese M., Soroka C. J., Ananthanarayanan M., Koeppel T. A., Schlosser S. F., et al. . (1997). The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113, 255–264. doi: 10.1016/s0016-5085(97)70103-3, PMID: PubMed DOI

Verkade H. J., Wolters H., Gerding A., Havinga R., Fidler V., Vonk R. J., et al. . (1993). Mechanism of biliary lipid secretion in the rat: a role for bile acid-independent bile flow? Hepatology 17, 1074–1080. PMID: PubMed

Vítek L. (2020). Bilirubin as a signaling molecule. Med. Res. Rev. 40, 1335–1351. doi: 10.1002/med.21660, PMID: PubMed DOI

Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., et al. . (2003). Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125, 825–838. doi: 10.1016/s0016-5085(03)01068-0, PMID: PubMed DOI

Wang Z., Guo H., Wang Y., Kong F., Wang R. (2014). Interfering effect of bilirubin on the determination of alkaline phosphatase. Int. J. Clin. Exp. Med. 7, 4244–4248. PMID: PubMed PMC

Xu S., Weerachayaphorn J., Cai S. Y., Soroka C. J., Boyer J. L. (2010). Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G126–G135. doi: 10.1152/ajpgi.00522.2010, PMID: PubMed DOI PMC

Yamamoto Y., Moore R., Hess H. A., Guo G. L., Gonzalez F. J., Korach K. S., et al. . (2006). Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J. Biol. Chem. 281, 16625–16631. doi: 10.1074/jbc.M602723200, PMID: PubMed DOI

Zamek-Gliszczynski M. J., Day J. S., Hillgren K. M., Phillips D. L. (2011). Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metab. Dispos. 39, 1794–1800. doi: 10.1124/dmd.111.040162, PMID: PubMed DOI

Zhang Y., Lickteig A. J., Liu J., Csanaky I. L., Klaassen C. D. (2020). Effects of ablation and activation of Nrf2 on bile acid homeostasis in male mice. Toxicol. Appl. Pharmacol. 403:115170. doi: 10.1016/j.taap.2020.115170, PMID: PubMed DOI PMC

Zhang Y., Limaye P. B., Lehman-Mckeeman L. D., Klaassen C. D. (2012). Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. PLoS One 7:e34522. doi: 10.1371/journal.pone.0034522, PMID: PubMed DOI PMC

Zhang F., Xi L., Duan Y., Qin H., Wei M., Wu Y., et al. . (2018). The ileum-liver farnesoid X receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats. Eur. J. Pharm. Sci. 123, 404–415. doi: 10.1016/j.ejps.2018.08.005, PMID: PubMed DOI

Zhao Y., Zhai D., He H., Liu J., Li T., Chen X., et al. . (2009). Matrine improves 17alpha-ethinyl estradiol-induced acute cholestasis in rats. Hepatol. Res. 39, 1144–1149. doi: 10.1111/j.1872-034X.2009.00557.x, PMID: PubMed DOI

Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis